Levamisole as adjuvant immunotherapy in breast cancer.
Results are reported of a double-blind randomized study on 198 patients with resectable node positive mammary cancer, evaluating the effect of the immune modulating drug levamisole in an adjuvant setting. Drug treatment was started after completion of postoperative radiotherapy. In a two-arm trial 97 patients used levamisole and 101 patients used a placebo. No difference was noted in overall survival and disease-free survival between the two groups. Toxicity was reason for discontinuation of the drug in 30 of 97 of the patients in the levamisole group and 8/101 in the placebo group.
D000328:Adult; D001943:Breast Neoplasms / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008593:Menopause; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies
D007978:Levamisole